Chugai Pharmaceutical Co., Ltd.
4519
Clasificación en acciones
#350
Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company,... Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company, operating subsidiaries involved in the full lifecycle of drug development, from research and manufacturing to sales, import, and export, serving both Japanese and international markets. Its commercialized product portfolio spans several key therapeutic areas. These include a robust oncology offering with leading treatments like Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda. Additionally, it provides medications for bone health (e.g., Actemra, Edirol, Bonviva), renal conditions (such as Mircera and Oxarol), and neurological or other diverse ailments (including Hemlibra, CellCept, and Enspryng). Beyond its existing offerings, the company maintains an active research and development pipeline. This pipeline features multiple promising candidates targeting oncology, orthopedic and joint disorders, autoimmune diseases, kidney-related conditions, and various neurological or other health issues. Strategic partnerships are central to Chugai's operations, most notably a significant alliance with the Roche Group. The company also fosters collaborative research initiatives with academic institutions. Established in 1925, Chugai's headquarters are located in Tokyo, Japan, and it operates as a key subsidiary of Roche Holding Ltd.
Precio por acción
$41.60
Capitalización bursátil
$68.46B
Cambio (1 día)
0.94%
Cambio (1 año)
-12.56%
País
JP
Comercio Chugai Pharmaceutical Co., Ltd. (4519)
Categoría
Healthcare
Margen Operativo de Chugai Pharmaceutical Co., Ltd. (4519)
Margen Operativo al October 2026 TTM: 47.24%
Según los informes financieros más recientes y el precio de las acciones de Chugai Pharmaceutical Co., Ltd., el margen operativo actual (TTM) es 47.24%. Al final de 2024, el margen operativo era 46.46%.
Historial de Margen Operativo de Chugai Pharmaceutical Co., Ltd. desde 2003 hasta 2026
Margen Operativo al final de cada año
| Año | Margen Operativo | Cambiar |
|---|---|---|
| 2026 (TTM) | 47.24% | 0.68% |
| 2025 | 46.92% | 0.99% |
| 2024 | 46.46% | 24.22% |
| 2023 | 37.40% | -11.75% |
| 2022 | 42.38% | -2.31% |
| 2021 | 43.38% | 11.23% |
| 2020 | 39.00% | 24.76% |
| 2019 | 31.26% | 40.24% |
| 2018 | 22.29% | 15.61% |
| 2017 | 19.28% | 19.53% |
| 2016 | 16.13% | -9.43% |
| 2015 | 17.81% | 5.63% |
| 2014 | 16.86% | -11.22% |
| 2013 | 18.99% | -2.37% |
| 2012 | 19.45% | 16.40% |
| 2011 | 16.71% | -4.24% |
| 2010 | 17.45% | -9.40% |
| 2009 | 19.26% | 22.13% |
| 2008 | 15.77% | -18.46% |
| 2007 | 19.34% | 8.11% |
| 2006 | 17.89% | -26.07% |
| 2005 | 24.20% | 38.44% |
| 2004 | 17.48% | -4.74% |
| 2003 | 18.35% | 0.00% |
Margen Operativo de empresas similares o competidoras
| Empresa | Margen Operativo | Diferencia de Margen Operativo | País |
|---|---|---|---|
| 49.72% | -98.95% |
US
|
|
| 25.70% | -99.46% |
US
|
|
| 29.32% | -99.38% |
US
|
|
| 16.65% | -99.65% |
US
|
|
| 26.59% | -99.44% |
CH
|
¿Qué es el Margen Operativo de una empresa?
El Margen Operativo es un indicador clave para evaluar la rentabilidad de una empresa. Un margen operativo más alto suele ser mejor, ya que indica que una empresa puede vender sus productos o servicios por mucho más de lo que cuestan producirlos. Se calcula dividiendo las ganancias de la empresa entre sus ingresos.